Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine 2% infiltration in tubeless percutaneous nephrolithotomy for singular pelvic stone
IRCT20221108056446N17Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bupivacaine in nephrolithiasis, sponsored by Isfahan University of Medical Sciences. Started Jul 2025; status: completed.
02
Drugs
bupivacaine
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on IRCT20221108056446N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221108056446N17.